Indication: Urothelial Cancer

A Phase III, Randomized, Open Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination with Standard of Care Chemotherapy and Durvalumab in Combination with Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients with Unresectable Locally Advanced or Metastatic Urothelial Cancer. (D933SC00001)

Unresectable Locally Advanced or Metastatic

Sub-indication: Unresectable Locally Advanced or Metastatic Urothelial Cancer.

Line of Therapy: 1st Line. (Patients who have received prior definitive chemoradiation, adjuvant or neoadjuvant for locally advanced disease are eligible provided that progression to locally advanced or metastatic disease has occurred >12 months from the last therapy or >12 months from the last surgery.)

Drug Study

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: AstraZeneca

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.